Evercore Has Lowered Expectations for Cencora (NYSE:COR) Stock Price

Cencora (NYSE:COR) had its price objective reduced by equities research analysts at Evercore from $440.00 to $420.00 in a report issued on Thursday, MarketBeat Ratings reports. The firm currently has an “outperform” rating on the stock. Evercore’s price objective suggests a potential upside of 16.94% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Wells Fargo & Company boosted their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird set a $415.00 target price on Cencora in a report on Tuesday, January 13th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Barclays initiated coverage on Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target for the company. Finally, Mizuho upped their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $394.75.

Cencora Trading Up 2.0%

NYSE:COR opened at $359.15 on Thursday. The company has a market cap of $69.67 billion, a P/E ratio of 43.17, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68. Cencora has a twelve month low of $237.71 and a twelve month high of $377.54. The business has a 50 day moving average price of $345.91 and a two-hundred day moving average price of $325.92. The company has a quick ratio of 0.55, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same period last year, the company earned $3.73 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year. As a group, analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Oakworth Capital Inc. acquired a new stake in Cencora during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC bought a new stake in Cencora in the 4th quarter valued at $27,000. Archer Investment Corp grew its holdings in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares in the last quarter. Finally, IAG Wealth Partners LLC bought a new position in Cencora during the 3rd quarter worth $30,000. 97.52% of the stock is owned by institutional investors.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.